Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab
Susan M. O'Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology... Author: ScrippsHealth Added: 03/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2016 Category: Cancer & Oncology Source Type: podcasts

How to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting
Susan M. O'Brien, MD of University of California Irvine discusses how to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting at Scripps Health 36th Annual Conference: Clinical Hemato... Author: ScrippsHealth Added: 03/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2016 Category: Cancer & Oncology Source Type: podcasts

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refr... Author: VJHemOnc Added: 02/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 10, 2016 Category: Cancer & Oncology Source Type: podcasts

ENRICH clinical trial for untreated mantle cell lymphoma
Prof. Simon Rule from Derriford Hospital, Plymouth, UK, talks about the ENRICH clinical trial, whihc is looking at the use of ibrutinib and rituximab in newly diagnosed mantle cell lymphoma patients. ... Author: PatientPowerEU Added: 01/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 18, 2016 Category: Cancer & Oncology Source Type: podcasts

ASH Clinical News: Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL
ASH Clinical News talks to Laurie Sehn, MD, MPH, about the “remarkable” results from the phase III GADOLIN trial – the first randomized trial to investigate obinutuzumab plus bendamustine in patients ... Author: ash Added: 12/21/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 21, 2015 Category: Cancer & Oncology Source Type: podcasts

Idelalisib + Rituximab Successful in Frontline with Some Toxicity
Susan M. O’Brien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some ... Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Adverse Events with Idelalisib + Rituximab May Be Autoimmune Related
Susan M. O’Brien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about the Adverse Events with Idelalisib + Rituximab May Be Autoimmune R... Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib - Rituximab Combination for Relapsed CLL Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

New Anti-CD20 Antibodies for CLL - Are They Better than Rituximab?
Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a series that focuses on controversial areas in the management of hemato... Author: imedex Added: 12/05/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 5, 2015 Category: Cancer & Oncology Source Type: podcasts

November 3 2015 Issue
1) Neurology® Neuroimmunology & Neuroinflammation: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Isabel Illa about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Dr. Ted Burns is interviewing Dr. Murray Grossman for our ...
Source: Neurology Podcast - November 2, 2015 Category: Neurology Authors: American Academy of Neurology Source Type: podcasts

Debate: A Case of Stage IV Follicular Lymphoma - Rituximab or
Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a series that focuses on controversial areas in the management of hemato... Author: imedex Added: 11/02/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 2, 2015 Category: Cancer & Oncology Source Type: podcasts

HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL | Dr Jacqueline Barrientos at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS t... Author: EMJ Added: 08/26/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2015 Category: Cancer & Oncology Source Type: podcasts

EHA 2015: Overall survival after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL
At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the overall survival analysis adjusting for trea... Author: VJHemOnc Added: 07/22/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 22, 2015 Category: Cancer & Oncology Source Type: podcasts